Teijin Pharma Limited

Satoshi Yamamura

Hiroshi H Eguchi

Akira Tanokura

Kenichiro Takagi

Naoko Namiki

Hirotsugu Kato

Hiroyuki Sugiyama

Hirofumi Higuchi

Takayuki Hara

Junji Igarashi

Johji Nomura

Kei Segawa

Daisuke Ishikawa

Masayo Ohori

Etsuko Mitsuyama

Tomoyo Takeo

Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.

Anti-IGF-I receptor humanized antibody

The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.

Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies

[Problem] The object of the present invention is to provide a novel compound having &#x3b2;2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity. [Means for Solving the Problem] The present invention is a quaternary ammonium salt compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, with superior &#x3b2;2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity. 

Quaternary ammonium salt compounds

Growing community of inventors

Tokyo, Japan

Satoshi Yamamura